Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

IRONWOOD PHARMACEUTICALS, INC.

(IRWD)
  Report
Real-time Estimate Cboe BZX  -  11:45 2022-10-04 am EDT
10.49 USD   +1.11%
09/08Insider Sell: Lantheus Holdings
MT
09/06Insider Sell: Ironwood Pharmaceuticals
MT
09/06Ironwood Pharmaceuticals Says Linzess Meets Primary, Secondary Endpoints in Phase 3 Trial in Pediatric Patients With Functional Constipation
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/28/2022 09/29/2022 09/30/2022 10/03/2022 10/04/2022 Date
10.63(c) 10.37(c) 10.36(c) 10.37(c) 10.49 Last
2 787 787 1 893 702 1 836 941 1 873 276 320 484 Volume
+3.51% -2.45% -0.10% +0.10% +1.16% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 422 M - -
Net income 2022 173 M - -
Net cash position 2022 417 M - -
P/E ratio 2022 10,6x
Yield 2022 -
Sales 2023 448 M - -
Net income 2023 247 M - -
Net cash position 2023 728 M - -
P/E ratio 2023 7,59x
Yield 2023 -
Capitalization 1 589 M 1 589 M -
EV / Sales 2022 2,77x
EV / Sales 2023 1,92x
Nbr of Employees 219
Free-Float 98,3%
More Financials
Company
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company that is focused on the development and commercialization of GI products in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC). It operates in the human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women... 
More about the company
Ratings of Ironwood Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about IRONWOOD PHARMACEUTICALS, INC.
09/08Insider Sell: Lantheus Holdings
MT
09/06Insider Sell: Ironwood Pharmaceuticals
MT
09/06Ironwood Pharmaceuticals Says Linzess Meets Primary, Secondary Endpoints in Phase 3 Tri..
MT
09/06Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS®..
BU
09/06Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of Linzess®..
CI
09/02Capital One Securities Initiates IRWD at Overweight with $15 Price Target
MT
09/01Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
BU
08/16Wells Fargo Adjusts Ironwood Pharmaceuticals' Price Target to $13 from $12, Maintains E..
MT
08/15Insider Sell: Ironwood Pharmaceuticals
MT
08/11Insider Sell: Ironwood Pharmaceuticals
MT
08/05Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guida..
AQ
08/04IRONWOOD PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
AQ
08/04Tranche Update on Ironwood Pharmaceuticals, Inc.'s Equity Buyback Plan announced on May..
CI
08/04Ironwood Pharmaceuticals Posts Lower Q2 Earnings, Revenue; Maintains 2022 Revenue Outlo..
MT
08/04Transcript : Ironwood Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 04, 2..
CI
More news
News in other languages on IRONWOOD PHARMACEUTICALS, INC.
09/06Vente d'initiés : Ironwood Pharmaceuticals
09/06Ironwood Pharmaceuticals déclare que Linzess répond aux critères primaires et secondair..
09/06Ironwood Pharmaceuticals annonce des résultats positifs de l'essai de phase III de Linz..
08/15Vente d'initiés : Ironwood Pharmaceuticals
08/11Vente d'initiés : Ironwood Pharmaceuticals
More news
Analyst Recommendations on IRONWOOD PHARMACEUTICALS, INC.
More recommendations
ETFs positioned on IRONWOOD PHARMACEUTICALS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Invesco Dynamic Biotechnology & Genome ETF - USD2.76%3.11%United_States
Virtus LifeSci Biotech Products ETF - USD1.72%2.01%United_States
Invesco S&P SmallCap Health Care ETF - USD1.7%1.24%United_States
ALPS Medical Breakthroughs ETF - USD1.2%4.04%United_States
SPDR S&P Biotech ETF - USD1.04%3.48%United_States
More ETFs positioned on IRONWOOD PHARMACEUTICALS, INC.
Chart IRONWOOD PHARMACEUTICALS, INC.
Duration : Period :
Ironwood Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IRONWOOD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 10,37 $
Average target price 13,20 $
Spread / Average Target 27,3%
EPS Revisions
Managers and Directors
Thomas A. McCourt President, Chief Executive Officer & Director
Sravan Kumar Emany Chief Financial Officer & Senior Vice President
Julie Harris McHugh Executive Chairman
Michael Shetzline Chief Medical Officer & Senior Vice President
Marcel Moulaison Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
IRONWOOD PHARMACEUTICALS, INC.-11.15%1 589
MODERNA, INC.-52.36%46 259
LONZA GROUP AG-36.15%36 760
IQVIA HOLDINGS INC.-34.00%33 784
SEAGEN INC.-10.93%25 236
ALNYLAM PHARMACEUTICALS, INC.18.03%24 025